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Abstract
Background: Research using electronic health records (EHRs) relies heavily on coded clinical data. Due to variation in coding
practices, it can be difficult to aggregate the codes for a condition in order to define cases. This paper describes a
methodology to develop ‘indicator markers’ found in patients with early rheumatoid arthritis (RA); these are a broader range
of codes which may allow a probabilistic case definition to use in cases where no diagnostic code is yet recorded.
Methods: We examined EHRs of 5,843 patients in the General Practice Research Database, aged $30y, with a first coded
diagnosis of RA between 2005 and 2008. Lists of indicator markers for RA were developed initially by panels of clinicians
drawing up code-lists and then modified based on scrutiny of available data. The prevalence of indicator markers, and their
temporal relationship to RA codes, was examined in patients from 3y before to 14d after recorded RA diagnosis.
Findings: Indicator markers were common throughout EHRs of RA patients, with 83.5% having 2 or more markers. 34% of
patients received a disease-specific prescription before RA was coded; 42% had a referral to rheumatology, and 63% had a
test for rheumatoid factor. 65% had at least one joint symptom or sign recorded and in 44% this was at least 6-months
before recorded RA diagnosis.
Conclusion: Indicator markers of RA may be valuable for case definition in cases which do not yet have a diagnostic code.
The clinical diagnosis of RA is likely to occur some months before it is coded, shown by markers frequently occurring
$6 months before recorded diagnosis. It is difficult to differentiate delay in diagnosis from delay in recording. Information
concealed in free text may be required for the accurate identification of patients and to assess the quality of care in general
practice.
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Introduction
Electronic health records and their potential for research
and clinical audit
Electronic health records (EHR) are a key data source for
health-related research [1,2]. EHR systems are developing rapidly
in the US in response to government directives and incentives
[3,4]. EHRs in the UK are most advanced in primary care where
they provide complete electronic data about primary care
consultations, as well as a summary of care received elsewhere
and reported to the practice. EHRs are now seen as valuable
resources for research such as healthcare provision audits, disease
registries, and epidemiological studies [5,6]. Traditional epidemi-
ological studies have either used data collected within the study in
purpose-built datasets [7,8,9] or used routine hospital data which
have gone through a separate coding stage (e.g. Hospital Episode
Statistics). These can be considered as ‘‘static’’ data, by contrast
with ‘‘live’’ electronic health data, produced and coded in the
context of clinical consultation and shaped by the context of
recording. Many factors influence recording, from financial
incentives to the desire to protect a patient from stigma – and
these can often change rapidly over time [10]. This means that
defining and finding all cases of the disease of interest can be
problematic. This paper describes a methodology to maximise the
probability of finding cases in EHRs by developing ‘‘indicator
markers’’ which are codes that may be combined to make a
probabilistic or logical definition of a case in conjunction with, or
in the absence of, a diagnostic code. We describe the development
of these markers for cases of rheumatoid arthritis (RA) and explore
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the utility of these markers for case definition in the early
presentation of RA.
The use of indicator markers instead of solely diagnostic
codes
When general practitioners (GPs) code the results of clinical
consultations, they may not apply a diagnostic code on the first
suspicion of a diagnosis, especially of a complex or chronic disease.
Instead they may code symptoms, tests or referrals for a specialist
opinion. The first firm diagnosis may be found in the text of a
specialist’s letter to the GP which is attached to the record but
coded under an administrative code such as ‘‘letter from
specialist’’. The diagnostic code may only be recorded in the
EHR when, for example, a specialised drug prescription is issued.
The date of recording of the diagnostic code may therefore bear
little relationship to the date of actual diagnosis.
When using EHRs to examine the presentation and diagnosis of
a specific condition, it is therefore not sufficient to rely upon the
diagnostic codes alone for case definition. Such practice will miss
cases for which a diagnostic code has not yet been recorded, and
may also misrepresent the date of diagnosis and result in the loss of
valuable information about presentation and diagnosis which
comes before the code. Two systematic reviews of EHR data
quality in the UK [11,12] found the recording of diagnostic codes
for diseases varied, from 40% agreement with other sources for
angina, up to 100% for myocardial infarction and diabetes, both
of which have clear diagnostic criteria or their recording
incentivised in the UK’s national health service. Several studies
suggest that cancer, for example, is not recorded systematically.
Pascoe and colleagues [13] found that when comparing GP
records to a cancer registry, 19.3% of patients had no code for a
malignancy in their GP records, but that by combining codes for
malignancy, abnormal test results and prescriptions they could
identify 96.3% of cancer patients in their sample. Tate and
colleagues [14] found evidence that a cancer code was recorded
late in the diagnostic process, with relevant investigations found in
almost three quarters (71%) of patients in the year before the date
of recorded diagnosis and 87% having relevant recorded
symptoms. In addition, 7.5% had evidence of cancer treatment
or oncology referral before any specific mention of cancer as a
diagnosis in the EHR.
In order to define cases of the disease of interest in an EHR, it is
therefore not sufficient to rely solely on diagnostic codes [15].
Instead it is necessary to draw up lists of a range of related codes,
such as symptom, referral, test or treatment codes, which are
strongly associated with, and indicative of, the disease of interest.
We term these codes ‘‘indicator markers’’. Indicator markers may
be used singly or in combination to indicate the suspicion of, or
presumptive presence of, the clinical entity.
The methodology of drawing up code-lists
Even for studies using only diagnostic codes, the methodology of
drawing up code lists for any given clinical entity is poorly
described in the literature. Preparing lists for all the various entities
that need to be considered within a study – case definition,
endpoints, covariates – is a major undertaking. Researchers
working on similar diseases in different settings may replicate effort
in drawing up code-lists as there is rarely standardisation or
transparency to the process. This lack of collaboration means that
code-lists and case definitions may vary across studies. Variations
in code lists may lead to cases being missed or identified cases
differing between studies, and create biased, inaccurate or non-
replicable results [15,16]. Similarly, incidence estimates may be
affected leading to inaccurate assessment of the health need, which
in turn may have major implications for commissioning and the
distribution of resources.
Code lists for studies using primary care EHRs are normally
prepared through an a priori process of consultation between
researchers, GPs and disease specialists [17,18]. A dictionary of
Read codes (the hierarchical system for coding diagnoses,
symptoms and procedures used in UK primary care) is consulted,
and relevant codes selected, which are then operationalised in a
case definition. Cases of a disease or ‘‘clinical entity’’ are often
defined by the first occurrence of a diagnostic Read code
considered as sufficient to define a case (e.g. cancer of the colon).
We propose that cases can also be identified by combinations of
Read codes and other categories of coded data (e.g. migraine
could be ascertained by the occurrence of general terms for
headache, together with multiple prescriptions of a migraine
specific drug). The multiplicity of potentially relevant data types is
shown in Figure 1. A range of these may be combined to form a
probabilistic or logical definition. The data types which contribute
to case definition of a clinical entity may vary from diagnosis,
through symptoms, to consultations and recording of correspon-
dence and may not be confined to the health data of individuals,
but may include social, demographic and lifestyle factors. In
addition to coded data in the record, much information may be
hidden in free text portions of the EHR and this concealed
information has very rarely been used to classify cases [19].
Computer based methodologies for reliably extracting written
clinical information are still in their early stages [20]. Several
authors have shown that including data from free text increases
case ascertainment for both acute conditions such as respiratory
infections and chronic diseases such as angina [21,22,23] as well as
RA [19] and can enhance estimates of symptoms in cancer
presentation by 40% [24]. Indicators of a disease can be drawn
from both coded data and the free text in the record. This study
focuses on the use of coded data for this purpose.
Rheumatoid arthritis as an exemplar
Using descriptions of the early presentation and management of
rheumatoid arthritis (RA) in primary care as an exemplar, we
aimed to demonstrate the potential impact of supplementing
existing approaches to case definition using an a posteriori, data
driven approach. We hypothesised that if a broad range of
indicator markers are to be used to identify cases of RA, they could
not be exclusively drawn up using an a priori method. Instead, to
form a truly comprehensive list of these codes, some scrutiny of
data within RA patients’ records would be needed. The
consequent list of codes developed was then examined for its
ability to augment our ability to (i) identify recently incident cases
of RA, and (ii) provide information about the diagnostic process in
primary care.
Rheumatoid arthritis was selected because robust data on the
diagnosis and management of RA in primary care setting is lacking
and referral practices are highly variable across the NHS in the
UK. However, there is increasing evidence that early intervention
with disease modifying anti-rheumatic drugs (DMARD) improves
prognosis [25]. Such early intervention requires early recognition
and referral to specialist services. Reliable case definition would
enable better estimation of presentation and service use as well as
facilitate research on this disease. It was hypothesised that there
would be significant activity in the record indicative of RA
presentation before an RA code was found in the record. RA is not
an incentivised condition in UK primary care and there are no
universally used codes so identification is problematic. This fact,
however, also gave us the opportunity to explore coding in a
Electronic Health Records for Rheumatoid Arthritis
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disease for which there are no agreed coding standards and in
which coding practices may vary widely.
Objectives
Our objectives were to:
1. Draw up a comprehensive list of indicator markers for the early
presentation and diagnostic process of rheumatoid arthritis.
2. Describe how much additional information is acquired by
supplementing the a priori code lists with the a posteriori
approach.
3. Explore the extent to which the indicator markers could a) be
used to identify cases of rheumatoid arthritis prior to an RA
diagnostic code and b) describe the diagnostic process of RA in
primary care.
4. Explore differences in the recording of indicator markers
between genders to confirm that there were no systematic
differences between genders which would affect case definition.
Methods
Ethics Statement
The study was approved by the MHRA Independent Scientific
Advisory Committee (protocol number 09_033R).
Population and participants
The General Practice Research Database (GPRD) is an
electronic database of anonymised longitudinal patient records
from general practice [1]. Established in 1987, it is a nationwide
dataset currently covering 8.5% of the population, with data from
over 600 practices, broadly representative of the UK population.
There are 5.25 million currently active patients (in January 2012).
Records are derived from a widely used GP software system
(VISION) and contain complete prescribing and coded diagnostic
and clinical information as well as information on tests requested,
laboratory results and referrals made at or following on from each
consultation. The structure of the data is shown in Figure 2, with
different elements of data held in separate record tables. Each
clinical event has a code assigned by the GP using the Read coding
system, version 2. General practitioners enter medical diagnoses
and symptoms using these Read codes. Read codes are a
hierarchical recording system used to record clinical summary
information. The codes are not limited to diagnostic and
procedural codes, but also include codes for symptoms, test
results, screening, history and other areas.
Our target population was permanently registered patients in
the GPRD within the study period (1/1/2005 to 31/12/2008).
From this group we identified patients with a first diagnostic code
for RA between 1/1/2005 and 31/12/2008 who were aged
30 years and over at the time of diagnosis.
Development of indicator markers
Figure 3 provides an overview of the preparation of the lists of
indicator markers. Lists of diagnostic codes for rheumatoid
arthritis, used to define the cases used in this study, were also
drawn up using the a priori methods described here. The methods
used two complementary approaches:
1. a priori development using clinical opinion, code hierarchy
and dictionaries.
2. a posteriori modification examining the records of identified
RA cases to supplement lists with codes actually used in these
records in the period leading up to RA diagnosis.
A priori development of indicator markers
We were seeking to capture events and consultations involved in
the presentation and early management of inflammatory arthritis
and which would be recorded in the electronic health record. The
lead researcher (AN) met with two rheumatologists (KAD and one
other), as well as two GPs (HS, GR) to discuss how patients with
early inflammatory arthritis might present and how this might be
recorded by the GP in codes in the primary care record. The
following domains were considered: diagnoses; symptoms; signs;
tests; referrals; treatment. Within each domain, this group of four
clinicians identified possible markers of RA presentation along
with key terms that might be used to record this presentation
Figure 1. Data types contributing to characterisation of a clinical entity.
doi:10.1371/journal.pone.0054878.g001
Electronic Health Records for Rheumatoid Arthritis
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e54878
(Table 1). Those marked with asterisks were felt to be most specific
and were selected as the initial markers.
We then undertook searches for Read codes used to represent
these markers of RA presentation. This was designed to be an
inclusive, sensitive search strategy leading to the production of lists
of potential codes to be considered. The following combination of
techniques was used, often in an iterative fashion.
1. Text searching. This was carried out in the medical
browser supplied by the GPRD which lists the codes available to
GPs to use in the records. Using the list of keywords that might be
used for each marker we searched in as many fields (primarily the
Read-Oxmis-Code table) as possible to find suitable codes.
2. Using the code hierarchy. By examining the Read codes
obtained from text searches, the main Read code groups involved
were identified. Using the NHS Browser, which lists Read codes in
hierarchies, related areas in the hierarchy were identified and
searches were then repeated including these terms and code-
groups.
Figure 4 summarises the marker groups which underpinned the
searches that were undertaken. Full details are available in
Appendix S1. The search process was complicated by the structure
of the Read code hierarchy because the codes for diagnoses and
presenting symptoms of musculoskeletal disorders are not clearly
differentiated. In order to maintain a complete record of the
methods, all codes returned by each search were saved. Code-lists
used for studies of RA available from other researchers were
reviewed and this led to 15 extra codes being included [15].
Search results were then collated and ten duplicates removed,
resulting in a total of 1248 codes relating to markers indicating
some aspect of RA presentation. A classification system was
prepared so that codes were classified to correspond to provisional
indicator marker groups and those that were not relevant to these
groups were discarded, with documentation of the process. All
codes identified in the searches were examined for relevance and
to assign them to marker groups, separately by two clinically
trained investigators, AN and either GR or HS. Disagreements
were discussed by the coders and if not agreed referred to third
party (KD, GR or HS).
A posteriori modification of indicator markers
We used data from previously identified RA cases in three ways
to confirm or modify the a priori marker lists drawn up during the
first process.
1. Commonly-used codes. The complete records of an
initial random sample of 1,743 RA cases defined using the
rheumatoid arthritis or juvenile inflammatory arthritis codes in the
a priori provisional code list were examined. All the codes that
related to RA presentation in the year preceding diagnosis were
totalled. Any codes that had been used in more than 50 cases but
had not been included in the a priori marker code lists were
reviewed. These codes included a group that described non-specific
investigations such as C-reactive protein levels, anti-nuclear antibody
or other auto-antibody tests. These were added as new marker
group. Additional symptom codes for knee pain and neck pain
were added to the other symptoms marker and polymyalgia
rheumatica was added to the other named inflammatory arthritis
diagnosis marker.
2. Patient histories. For selected time periods all the codes
used in 30 randomly selected RA patients from the sample above
were reviewed. The time periods selected were 30 days either side
of first referral code, first Disease Modifying Anti-Rheumatic Drug
(DMARD) prescription (especially if more than six months before
diagnosis), and 30 days either side of the first one out of
inflammatory diagnosis, rheumatoid factor test, and non – specific
investigation code (especially if these were more than six months
before diagnosis). This review revealed that one code for psoriatic
arthropathy had been missed. It additionally suggested that many
oral steroid prescriptions were unrelated to arthritis, so the codes
for DMARD were revised to remove steroids. It also revealed use of
codes for monitoring DMARD usage. New searches were undertaken
for codes related to drug monitoring, the results were classified by two
coders and the agreed codes added to the DMARD code-list.
3. Pre-anonymised text. We had access to 10,000 entries of
pre-anonymised text from the GPRD unrelated to this study
dataset. These had been used in a variety of other studies,
including an investigation into the use of non-steroidal anti-
inflammatory drugs. The free text entered in association with 1307
codes which were one of the assigned a priori codes or had the term
Figure 2. Schematic model of the GPRD database.
doi:10.1371/journal.pone.0054878.g002
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arthritis in the text was reviewed. Terms in text that might be useful
in identifying cases were added and new searches performed (as in
the a priori code – searching process) and classified using methods
described above. This led to a marker of synovitis being created
(Figure 4).
Final code-lists for the indicator markers are in Appendix S2.
Markers were separated into specific markers of rheumatoid arthritis
(inflammatory arthritis, other inflammatory condition, referral to
rheumatology, rheumatoid factor test, synovitis or DMARD
prescription) and non-specific markers (non-specific or other arthritis
diagnosis, non-specific inflammatory or auto-immune investiga-
tions, joint signs and symptoms and NSAID prescriptions). No
changes were made to the diagnostic codes for Rheumatoid
Arthritis or Juvenile Inflammatory Arthritis in this a posteriori
modification process.
Identification of cases
All patients with a first coded diagnosis of RA (from an a priori
list of diagnostic codes) and aged 30 years or more at the time of
diagnosis were identified in the study period (2005–2008). Patients
who had an RA code anywhere in their record before the study
period were not included. GPRD allows for a date to be entered
for an event, in case this differs from the date the event was
recorded. However, if an event date had not been entered into the
GP system, the date that the record was created was used (10,986
events (0.1%) were imputed). Events were discarded if they
occurred before the start date (the later of the patient’s registration
date or the date that the practice’s records were considered up-to-
standard by the GPRD) or after the end date (the earlier of the
date of the patient leaving the practice or the last date records
were received from the practice). The indicator markers (asterisked
Figure 3. A priori and a posteriori strategies for developing code lists.
doi:10.1371/journal.pone.0054878.g003
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in Table 1) were identified in the records within one year of RA
diagnosis. Having established the markers, we then sought these
codes throughout the records of RA patients. To standardise
follow up times, analyses were restricted to RA cases who had
records for at least three years before through to 14 days after the
first coded RA diagnosis. All records were cut off at three years
prior to diagnosis. The first diagnostic code had to be within the
study period (2005–2008) but indicator marker events occurring
before the study period were included in analyses.
Statistical analysis
The data were prepared using Stata version 11 (Statacorp LP,
Texas). For each indicator marker, any relevant code from any
GPRD entry resulted in a positive marker. Within a marker group,
the date of the earliest code was taken as the first example of an
indicator for that patient and the date intervals were calculated
from this earliest code. For medication markers (DMARD and
NSAID) we looked for the presence of a prescription of these
medications. The prevalence of different indicator markers was
compared using chi-squared tests. The time interval between the
first indicator marker within a group and the first coded diagnosis
of RA was calculated. Since the time-intervals were skewed,
medians and non-parametric tests were used to compare groups
(Mann Whitney U). Survival analysis was performed constructing
survival time from 14 days after diagnosis backwards to three
years, with the earliest code in any indicator marker group as a
failure event.
Results
Results describe the value of the addition of indicator markers to
diagnostic code case definitions and how their exploration changes
the view of RA management in primary care.
Cases defined by diagnostic codes
Cases were defined by a first occurrence of an RA diagnostic
code during the study period (and no code prior to this in their
entire record). The study sample comprised 5,843 cases of RA, of
which 1,831 were men and 4,012 were women. Men were older
(median age 63 years; inter-quartile range, (IQR) 51–73) than
women at the time of diagnosis (median age 60 years; IQR 50–71,
p,0.001).
Table 1. Initial list of indicator markers for early inflammatory arthritis across different clinical domains, based on round-table
clinical discussions.
Diagnosis Symptoms Signs Investigations Therapy
*Rheumatoid arthritis *Stiffness especially morning *Polyarthritis *Rheumatoid factor *NSAID
*Inflammatory arthritis *Painful joints especially hands/
feet/wrists
*Joint effusion (not knee) C-reactive protein *DMARD
*Arthritis NOS Pyrexia of Unknown Origin Synovitis ESR (erythrocyte
sedimentation rate)
Steroid (non-oral)
*Palindromic RA Night sweats Anaemia Cox II inhibitors
*Reactive arthritis Fever X-rays hand & feet (not knee)
Reiter’s syndrome Auto-antibodies
Fibromyalgia Thyroid function tests
Lupus
Sicca syndrome
*these markers were selected for initial searches.
doi:10.1371/journal.pone.0054878.t001
Figure 4. Indicator marker groups.
doi:10.1371/journal.pone.0054878.g004
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Prevalence of Indicator Markers
Table 2 summarises the prevalence of the indicator marker
groups both in the whole study period and within particular time
periods. The most common specific marker was a rheumatoid
factor test, for which 62.9% patients had a code. There were codes
for referral to rheumatology services in 42.4% of patients. Codes
for clinical findings related to any inflammatory arthritis were
uncommon, present in only 14.8% of patients. Likewise synovitis
codes were present in only 4.1%. A third (33.6%) of patients had a
prescription for a DMARD and in 14% of patients this had
occurred at least six months before the diagnosis of RA was coded.
Overall, 86.0% of patients had one or more specific indicator
markers including DMARD prescriptions, with 34.2% having one
marker, 30.5% having two markers and 21.3% having three or
more specific markers.
Non-specific markers. were more common in the records
but these may reflect activity relating to events other than RA. The
most common indicator marker was a prescription for a non-
steroidal anti-inflammatory drug (NSAID) which was present in
over three-quarters of patients (79.3%). Two-thirds of patients
(66.1%) had evidence of a non-specific investigation, such as CRP
or autoantibody level and two-thirds (65.4%) had evidence of
other joint signs and symptoms. Non-specific arthritis diagnoses
were found in 18.0% of patients. Overall 94.5% of patients had
one or more non-specific indicator markers. When NSAIDs were
excluded from this analysis, as they may have been prescribed for
many conditions other than RA, 86.0% of patients had at least one
non-specific marker, with 32.8% having one, 42.8% having two,
and 10.4% having three non-specific markers.
In this sample, only 4.9% of patients (288) had no indicator
markers whether specific or non-specific. Only 11.5% (674)
patients had a single indicator marker, whereas 18.3% had two
markers, 23.6% had three markers, 21.1% had four markers and
20.5% of patients had five or more indicator markers in their
record before the RA diagnostic code was recorded.
Combinations of Markers
The combinations of specific indicator markers were examined
to assess their utility in presumptive case definition. These are
shown in Table 3. The most common specific indicator markers
(DMARD prescription, referral to rheumatology and rheumatoid
factor test) were assessed in combination with each other, as well as
with joint signs & symptoms from the non-specific markers.
DMARD prescription. This was commonly found in com-
bination with other markers: 1175 patients (20.1%) had both a
DMARD prescription and a referral to rheumatology services
before their RA code, 1032 (17.7%) had both DMARD and a
rheumatoid factor test and 1263 (21.6%) of patients had DMARD
and a non-specific joint sign or symptom.
Referral. 1640 patients (28.1%) had both a referral to
rheumatology services and a rheumatoid factor test coded in their
file before the RA code was recorded and a similar number (1764;
30.2%) had both a referral and a joint sign or symptom.
Rheumatoid factor test. Nearly half of patients (2670;
45.7%) had codes for both a rheumatoid factor test and a joint sign
or symptom.
When the three most common specific markers were investi-
gated (DMARD prescription, referral and rheumatoid factor test),
it was found that 1846 patients (31.6%) had two of these markers
and 667 patients (11.4%) had all three of these markers in their file
before an RA code was recorded. When joint signs & symptoms
was added to this list, 2080 patients (35.6%) had two of these
markers, 1426 patients (24.4%) had three markers and 531 (9.1%)
had all four of these common markers.
Prevalence of Markers by Gender
The prevalence of markers was similar in men and women as
shown in Table 4. Only two marker groups showed statistically
significant gender differences in prevalence. Diagnosis of a named
inflammatory arthritis was more common in men, 8.3% compared
to 6.5% in women (chi square = 6.18, DF = 1; p = 0.01) (not
shown in table). A DMARD prescription was also more frequent
in men, 35.7% compared to 32.6% in women, (chi square = 5.47,
DF = 1; p = 0.02), although when a Bonferroni correction was
applied for multiple comparisons, these differences were no longer
significant.
Timing of Markers
The timings of the first occurrence of the indicator markers in
relation to RA diagnostic code are shown in Table 2 and Table 4.
Referral to rheumatology services, rheumatoid factor tests and
DMARD prescriptions were coded closest in time to diagnosis,
whereas non-specific markers such as general investigations or
symptoms were frequently present more than a year before
diagnosis. It was found that 20.6% of patients had a rheumatoid
factor test coded more than six months before a specific diagnostic
code was recorded, 16.8% had a referral to rheumatology and
14.4% had a DMARD prescription. Overall, 44.7% of patients
had a specific marker occurring more than six months before a
diagnostic code was recorded. Intervals between markers and RA
diagnostic code were longer in women than men for non-specific
auto-immune type investigations (men 147 days (median), women
189 days; p = 0.006), for presentation of joint signs and symptoms
(men 323 days (median), women 448 days; p,0.001), and for first
evidence of referral (men 88 days (median), women 109 days;
p = 0.02).
Figure 5 shows ‘‘survival’’ curves for selected indicator markers,
with time reversed, from 15 days after diagnosis to three years
before diagnosis with a ‘‘failure event’’ being the earliest marker in
that indicator category. The curves show that rheumatoid factor
tests, referral and DMARD most often occur close to diagnosis
with a more gradual occurrence more than one year previously.
Discussion
This study described in detail a two stage, iterative process for
drawing up code lists and looked at the utility of indicator markers
prior to the definitive diagnostic code in a) the description of early
care, and b) the case definition, of rheumatoid arthritis patients,
with a view to defining uncoded cases (false negatives). Following a
panel of clinicians drawing up a first list of codes, data from RA
patients was scrutinised to see if additions to the lists should be
made. The second stage of this process resulted in considerable
modification of the lists, suggesting this is a valuable addition to
traditional methods of approaching code list design. The indicator
markers chosen were found to exist in the file well before the RA
diagnostic code and to give important information on the
diagnostic process of RA. Indicator markers were wide-spread in
the records of RA patients with 83.5% of patients having at least
two markers in their file before the RA diagnostic code was
recorded.
This strategy of drawing up code lists, with the combination of a
priori and a posteriori data-driven stages, will be applicable to other
conditions and coding systems. Using the second stage, a posteriori
approach allowed us to make significant modifications to code lists.
For example, synovitis and non-specific auto-immune investiga-
tions had been raised by the expert group at the initial stages but
not included in the a priori searches as they were considered too
non-specific. However, they were discovered, during the data-
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driven stage, to be found with some regularity in the records of RA
patients. The data-driven stage then revealed codes that had been
missed and some errors in classification and so served as a form of
triangulation. The finding that this data-driven modification stage
is of such importance poses a challenge to researchers and data
providers, as this additional stage of code searching may not be
possible in the design stage of all research studies, due to difficulties
with advance access to data.
Secondly, our study looked at the value of using indicator
markers to understand the diagnostic process of early RA as
presenting in primary care. Using these markers, we aimed to
indicate locations in the EHR where the diagnosis of RA was
being considered and to describe the early course of disease
presentation in these patients, as shown by coded symptoms of the
disease, referrals to appropriate services or because of tests being
ordered or results recorded. Indicator markers were widespread
within the RA patient records, in many cases a long time before
the RA diagnostic code was found on the file. These results
suggest, as was hypothesised, that the diagnosis of RA may have
been known about for some time before a diagnostic code was
added, with specific markers frequently found more than six
months before recorded diagnosis. This discrepancy between dates
may indicate diagnostic uncertainty or delay in coding a known or
presumptive diagnosis. Further field work would be needed to
Table 2. Prevalence of indicator markers during study period.
Marker present Timing of first marker within study period (in relation to RA diagnosis)
14 days after to ,1 month before 1–3 months before 3–6 months before 6 months – 3 yrs before
Non–specific inflammatory arthritis diagnosis or signs
n 867 209 143 124 391
% 14.8 3.6 2.5 2.1 6.7
Other named inflammatory condition
n 410 32 32 49 297
% 7.0 0.6 0.6 0.8 5.1
Referral to rheumatology services
n 2,480 725 467 306 982
% 42.4 12.4 8.0 5.2 16.8
RhF test – regardless of result
n 3,674 1326 657 488 1,203
% 62.9 22.7 11.2 8.4 20.6
Synovitis
n 241 46 44 33 118
% 4.1 0.8 0.8 0.6 2
DMARD prescription – excluding oral steroids
n 1,962 842 154 123 843
% 33.6 14.4 2.6 2.1 14.4
Any specific marker (date of earliest marker used)
n 2057 1395 771 607 2243
% 86.0 27.8 15.4 12.1 44.7
Non-specific arthritis diagnosis
n 1,053 200 224 151 478
% 18.0 3.4 3.8 2.6 8.2
Joint signs & symptoms
n 3,823 363 440 421 2,599
% 65.4 6.2 7.5 7.2 44.5
Non–specific investigations e.g. CRP, auto-antibodies
n 3,861 844 611 519 1,887
% 66.1 14.4 10.5 8.9 32.3
NSAID prescription
n 4,631 385 390 373 3,483
% 79.3 6.6 6.7 6.4 59.6
Any non-specific Markers (date of earliest marker used)
n 5524 404 370 400 4318
% 94.5 7.4 6.7 7.3 78.6
doi:10.1371/journal.pone.0054878.t002
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determine which of these two processes has most influence in these
data. UK guidance from NICE [25] suggests that RA should only
be diagnosed after it has been in evidence for 6 months. However,
these data precede this guidance and this is unlikely to be a full
explanation for the delay in diagnostic coding.
We were also able to explore gender differences in indicator
markers, to check for systematic differences in recording by
gender, but found no evidence of gender differences in the
prevalence of most, except for named inflammatory arthritis and
DMARD prescriptions both of which were more common in men.
The prevalence of referral and investigation markers was similar in
men and women although there was some evidence that the gap
between referral, non-specific symptoms, non-specific investiga-
tions and coding of diagnosis was longer in women than in men.
Thirdly, this study explored indicator markers as a way of
broadening case definitions in this disease, thereby potentially
identifying individuals with the disease who do not yet have a
diagnostic code. The majority of patients (83.5%) had two or more
indicator markers, and therefore combinations of codes may help
to describe the early presentation and diagnostic process of these
patients. One finding, however, was that the most common
symptom codes found in our study were the non-specific ones, and
these could relate to conditions other than RA. Despite this, 86%
of patients had at least one specific marker. When a combination
of the four most indicative markers were examined, it was found
that 36% had two of these markers, 24.4% had three markers and
9.1% had all four of these common markers. This suggests that
using these markers in combination may facilitate the identifica-
tion of RA cases, both in the early stages before an RA code is
recorded and in cases where no code has been recorded and the
cases would ordinarily slip ‘‘under the radar’’, leading to false
negatives and biasing a subsequent study.
However, these findings suggest that while coded indicator
markers do give a good indication of the presentation of RA, in
16.5% of patients there was no marker or only one marker before
the RA diagnostic code. With coded information alone it may not
be possible to reliably identify the early presentation of every case.
Extra information may be available in unstructured free text, and
may include both notes made by the GP during a consultation and
the content of referral letters and correspondence from specialists.
Information governance requirements mean that free text must be
anonymised before release to researchers. It is not currently
possible to do this reliably automatically and therefore manual,
expensive labour is required to ensure that datasets are
anonymised. Research projects using EHRs have therefore relied
almost exclusively on coded structured data rather than accessing
free text [12]. Text data is also difficult to analyse in large numbers
of patients and requires some form of processing or structuring to
Table 3. Frequency of combinations of indicator markers.
Code 1 Code 2 N (5843) %
DMARD Referral 1175 20.1
RhF Test 1032 17.7
Joint Symptom 1263 21.6
Referral RhF Test 1640 28.1
Joint Symptom 1764 30.2
RhF Test Joint Symptom 2670 45.7
DMARD, referral and RhF Test
- any two 1846 31.6
- all three 667 11.4
DMARD, referral, RhF Test and Joint symptom
- any two 2080 35.6
- any three 1426 24.4
- all four 531 9.1
doi:10.1371/journal.pone.0054878.t003
Table 4. Intervals between first indicator marker and diagnosis in RA cases (days).
n % Mean Median
25%
quartile
75%%
quartile n % Mean Median
25%
quartile
75%%
quartile
p for
gender
difference*
Inflammatory
arthritis
diagnosis
273 14.9 278 126 34 454 594 14.8 307 159 34 511 0.31
Rheumatoid
factor test
1,142 62.4 193 74 13 250 2,532 63.1 212 75 9 303 0.94
Referral 801 43.7 233 88 16 326 1,679 41.8 269 109 22 445 0.02
DMARD
prescription
654 35.7 321 51 0 693 1,308 32.6 351 103 0 749 0.23
Non-specific
arthritis
diagnosis
351 19.2 258 141 44 370 702 17.5 304 154 45 508 0.19
Non-specific
auto-immune
test
1,198 65.4 295 147 38 478 2,663 66.4 336 189 42 588 0.006
Joint
signs and
symptoms
1,186 64.8 424 323 94 747 2,637 65.7 481 448 129 813 ,0.001
NSAID
prescription
1,455 79.5 577 595 160 1010 3,176 79.2 614 689 194 1021 0.02
*non-parametric Mann-Whitney U test.
doi:10.1371/journal.pone.0054878.t004
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allow quantitative analysis [13]. The supplementation of coded
information with free text would significantly strengthen findings
in studies using EHRs, as has been found in previous studies of
case definition of RA using EHRs [19,26].
In order to identify a ‘‘case’’ for a study using EHRs we
therefore propose that there are three levels of classification for
sources of variation in recording, each level posing an increasing
challenge to the researcher. Level 1 consists of diagnostic codes
from within the same domain, such as different diagnostic codes
for rheumatoid arthritis. Because these are diagnostic codes, it is
probable that patients with these codes have the condition of
interest. However, the sole use of these codes may miss cases where
diagnostic coding is delayed or incomplete. At level 2, codes from
different domains are used, such as symptoms or test results rather
than a diagnosis e.g. ‘‘joint stiffness’’, ‘‘referral to rheumatology
clinic’’ or ‘‘rheumatoid factor positive’’. A combination of these
codes would result in a probabilistic definition of the condition, but
these coding patterns result in less certainty in the diagnosis for the
researcher and may also result in the inclusion of cases which do
not have the disease of interest. The final level, level 3, is where
additional disease specific information is found in free text – either
along with a more general diagnostic code or a code for a
symptom or a more general code such as ‘‘had a chat to patient’’.
Free text may supply additional information to allow a diagnosis to
be made with more certainty than if coded data alone were used.
How findings fit with previous literature
Literature on the methodology of drawing up code-lists for the
identification of cases, treatment or outcomes for health research is
sparse, despite its pivotal importance in such research. Some work
been published on the operationalisation of code-lists into
statistical programmes [27]. There are techniques available to
address the proliferation of diagnostic codes such as ancestor/
descendant tracing within SNOMED (‘‘Systematised Nomencla-
ture of Medicine Clinical Terms’’ – an international comprehen-
sive terminology system being adopted by the NHS), hierarchies
within Read codes and query building within clinical trial systems.
However, high-level search strategies, and how to address
variations in lists of codes below Level 1 variation (outlined above)
have not been discussed in the literature.
A lack of standardisation in methodology means that code-lists,
and hence case definitions, may vary across studies in a variety of
research contexts. Very little is known about how this variation in
code-lists affects study results, although there are implications that
it may be important, such as high rates of false negatives or
positives introducing biases in the estimation of uptake of certain
tests or treatments within disease populations [16,28]. An
additional concern is that the use and type of coding structures
may be individual to software systems so that the codes used to
describe, for example a polyarthritis, may differ across different
primary care software systems. Such system-specific coding
reinforces the need for a data-driven stage in any case-finding
process and the need to explore the data before finalizing code
selections.
Other authors have also highlighted the deficits from coded data
[29]. Jordan and colleagues showed that the number of
consultations related to knee pain were underestimated without
the use of text from primary care databases [21], and as mentioned
Tate and colleagues have shown that the diagnosis date of ovarian
cancer recorded in primary care records is later than other
evidence in the record [14]. This is consistent with our results
indicating that the diagnosis may have been known for some time
Figure 5. Survival curves for selected indicator markers in the 3 years preceding RA diagnosis, by gender.
doi:10.1371/journal.pone.0054878.g005
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before it was formally coded. In addition two studies have found
that using free text within algorithms for case definition
significantly improves the positive predictive value of subject
classification in RA when using EHRs [19,26].
Previous studies looking at the presentation and management of
early RA have been situated in secondary care and are therefore
prone to substantial referral bias [30,31,32]. The existing work
suggests that delay in seeking medical attention is a more
important factor than delay in recognition and referral to specialist
services [33]. Data from primary care describing the care process
from the first presentation are needed, but our results suggest that
this cannot be achieved within routine primary care electronic
databases using codes alone as much information, particularly that
which occurs outside primary care, may be recorded in free text.
Limitations
The indicator markers have not been validated by a review of the
associated text in the record and therefore it is possible that non-
specific codes, for example for a painful ankle, were unrelated to the
subsequent RA diagnosis. Similarly prescriptions for DMARD such
as methotrexate, and especially NSAIDs, may be unrelated to RA.
This will lead to an over-estimation of the presenting symptoms and
treatment in RA patients. The risk of under-estimation is perhaps
greater. This will occur if events or consultations relating to RA
diagnosis and management are missed because general codes have
been used and the important information recorded in text, which we
have described as level 3 variation. The next stage in the project is to
extract text around the time of indicator markers, and perform
keyword searches on extracted text.
Although we used a panel of four experts for generating the a
priori lists of indicator markers, a larger panel or a more in depth
process, such as a Delphi process, might have generated a different
or fuller list. However, other studies in this field have used similar
size panels of experts [15] to scrutinise possible codes. Indeed,
some studies have not drawn up lists but used a single diagnostic
Read code to identify RA patients [34,35]. We are not aware of
any studies which have reported the details of a data-driven stage
for modifying their lists. Greater clarity of reporting for drawing
up lists would result increased standardisation of case definition
and increase the generalisability of EHR study results. Previous
studies reporting validation of cases using EHRs have inadequately
described the methods for this validation [36]. We believe that this
documentation of the process is an important resource for
researchers new in the field, and encourage other researchers to
publish their code list strategies in a replicable way.
Furthermore we did not look at control data to compare the
incidence of the indicator markers in patients with no RA
diagnostic code. This comparison would be valuable to ascertain
whether these markers do indeed occur in greater numbers just
before an RA diagnostic code compared to at other times or in
other patients. Further work will examine these markers in control
data and also assess their utility in estimating the rates of false
negatives which may result by only using diagnostic codes for case
definition, thereby introducing bias into the study [28]. The use of
control data will allow us to estimate the positive predictive value
of clusters of indicator markers to ascertain which combinations
are most predictive of a RA diagnostic code being added to the
file. However, given the small proportions of patients with three or
more of the chosen codes in their record (around 10%) prior to the
RA code, there is likely to be more information concealed in the
free text which would contribute to case definition. Therefore our
plan is to extract this free text information to estimate its
contribution to case definition before estimating the predictive
value of clusters of indicators.
Implications for future research and practice
Preparing indicator markers and code-lists is time-consuming
and requires input from clinical experts. Context and temporal
relationships are often important in looking at markers and
building up patterns. It is likely to be a rate-limiting step in future
research projects – particularly if multiple clinical entities need to
be included in any one study. The design of future EHR systems
should consider the need for reporting and aggregation of cases
and facilitate the recording of the code-selection process, including
a data-driven stage and the ability to search within code-sets.
Future research might also consider whether machine learning
techniques could contribute to this process.
If EHRs are to be used appropriately in research we need to
develop a wider understanding of the drivers of coding in the
clinical environment. As work on different diseases develops, it
may also be possible to develop a typology of what kind of clinical
entities are liable to long gaps between the onset of clinical
suspicion, referral and treatment, and where the two are reliably
contemporaneous, in order to minimise wasted effort doing over-
complex analyses. Our findings here may generalise to some other
chronic diseases, but not all.
Sharing of resources between researchers is desirable, to avoid
unnecessary duplication. The process of breaking up search
strategies into different markers, with publication of precise search
terms and results, may allow transparency and replicability in the
preparation of code-lists and facilitate their sharing. For example
codes relating to a certain presentation might be stored and
available for use by another study. At present there is no
standardisation of methods for preparing case definitions and
code-lists which limits the possibilities of sharing results. No
recognised repository to aid sharing exists. Any standardisation
would require a common set of meta-data relating to case-finding
– detailing what has been done, decisions that have been made
and why. The format these meta-data should take is not obvious.
These findings emphasise the need for research using EHR to
go beyond simple use of diagnostic codes and adopt more
sophisticated strategies for case-finding, including the use of free
text. Relying on coded diagnosis may not lead to accurate case
definition thereby leading to inaccurate estimates for disease
registries and assessments of service needs. The development of
automated methods to allow access to information in text without
anonymisation should be an urgent priority.
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